Zimberelimab — Drug Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

2 Recruiting

10 Completed trials

9 Sponsors

14 Countries

Phase III

Phase II

Phase III: 4 Phase II: 11 Phase I/II: 1

Oversight events:

4 temporary halts 1 urgent safety measure 4 unexpected events across 4 trials

View oversight register →

Indications tested

Non-small cell lung cancer 3 Non-small cell lung cancer stage III 1 Thymic carcinoma 1 Anaplastic thyroid cancer 1 Gestational trophoblastic tumour 1 Non-small cell lung cancer stage II 1 Peritoneal mesothelioma malignant 1 Gastroenteropancreatic neuroendocrine tumour disease 1 Non-small cell lung cancer stage IIIB 1 Carcinoid tumour 1 Non-small cell lung cancer stage IIIA 1 Triple negative breast cancer 1

Sponsors using this IMP

Arcus Biosciences Inc. 4 Gilead Sciences Inc. 4 Hospices Civils De Lyon 2 AIO-Studien gGmbH 1 Fondation Franc.Cancerologie Digestive 1 Fondazione IRCCS Istituto Nazionale Dei Tumori 1 Fundacion GECP 1 Fundacion Para El Progreso De La Oncologia En Cantabria 1 Medica Scientia Innovation Research S.L. 1

All trials

16 total

PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co… Not authorised

2024-519922-19-00 Phase II 1 country Hospices Civils De Lyon
Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystec… Pending

2024-516943-14-01 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu… Pending

2024-517561-16-00 Phase II 1 country AIO-Studien gGmbH
Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer… Recruiting

2024-512960-75-00 Phase III 1 country Fundacion GECP
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting

2023-508302-24-00 Phase II 5 countries Gilead Sciences Inc.
An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien… Ended

2023-504420-26-00 Phase II 1 country Fundacion Para El Progreso De La Oncologia En Cantabria
Study with Various Immunotherapy Treatments in Participants With Lung Cancer Ended

2022-502916-35-01 Phase II 4 countries Gilead Sciences Inc.
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended

2023-507522-16-00 Phase III 9 countries Arcus Biosciences Inc.
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Phase III 8 countries Gilead Sciences Inc.
A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t… Ended

2024-511917-40-00 Phase II 1 country Arcus Biosciences Inc.
IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac… Halted

2024-517254-99-00 Phase II 1 country Hospices Civils De Lyon
N/A Ended

2024-513121-22-00 Phase II 3 countries Gilead Sciences Inc.
Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended

2022-503071-28-00 Phase III 4 countries Arcus Biosciences Inc.
A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Ended

2024-511158-36-00 Phase I/II 3 countries Arcus Biosciences Inc.
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LIN… Ended

2025-521489-80-00 Phase II 1 country Medica Scientia Innovation Research S.L.

Showing 1–16 of 16 trials

← All drugs A–Z